Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial
Study context
- Population
- Atrial fibrillation (AF) patients requiring oral anticoagulation (OAC) after successful percutaneous coronary intervention (PCI), randomised within 72 hours after PCIplanned sample size
- Participants
- 2,000 patients
- Planned comparison
- 30-day dual antiplatelet therapy (DAPT) strategy vs guideline-directed therapy
- Primary endpoint
- Major or clinically relevant non-major bleeding (superiority); composite of all-cause death, MI, stroke, systemic embolism or stent thrombosis (non-inferiority)
Methodological detailsrationale and design, investigator-initiated, international, open-label
- Rationale and design
- Investigator-initiated
- International
- Open-label
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial. EuroIntervention. Published 15 July 2024. doi:10.
Summarised from the published abstract; every number is checked against it